Zymeworks signs exclusive global licensing deal with Roche for cancer drug ZW209
ZYME•Zymeworks signed an exclusive global license and collaboration agreement with Roche for ZW209, a trispecific T cell engager targeting DLL3. Zymeworks will receive $55 million upfront and $40 million when a Phase 1b trial begins, with up to $718 million in additional milestones and tiered royalties.
1. Deal terms
Roche will fund the Phase 1a trial and has the exclusive right to develop and commercialize ZW209 globally. Zymeworks is eligible for tiered royalties ranging from high single digits to the mid-teens on global net sales, with patents extending into the 2040s.
